

Press Release

Lonza Acquires Research-Focused Chemical Company Zelum Based in New Zealand

- **Acquisition of Zelum Strengthens Lonza's Agro Ingredients and Wood Protection Businesses**

Basel, Switzerland, 3 August 2015 –Lonza announced today that it has acquired Zelum, a research-focused chemical company based in New Zealand (NZ), which develops and manufactures products for crop protection, specializing in fungicides, insecticides, herbicides, foliar nutrients and additives. Zelum also develops and manufactures products for wood protection. Zelum has facilities based in New Plymouth (NZ) with field research and timber facilities nearby in New Zealand, as well as in Australia and the United States.

"We see this acquisition as an excellent opportunity to further our growth strategy for Agro Ingredients by providing entry into new strategic markets and products that are complementary to our existing Meta[®] business," said Sven Abend, Chief Strategic Officer for Lonza. "It also allows Lonza to leverage Zelum's existing agrochemical business for registration and sales into other global regions, particularly the United States, EU and South America. Zelum's unique formulated products and patented delivery systems will benefit both the Agro Ingredients and Wood Protection markets."

Zelum is a leading developer and owner of patented chemistry and delivery technologies for pastoral crops and glue-line treatment of engineered wood. Zelum has 45 employees including a seasoned management team and experienced R&D team with highly skilled researchers and formulation chemists, as well as sales and technical people with strong industry experience.

For more than 25 years, Zelum has researched and developed smart products that meet specific needs of the agrochemical and timber treatment markets. Zelum has a reputation for responding quickly with first-rate research, testing, product development and enhancements. Zelum's manufacturing facilities are world class and include New Zealand's first micro-encapsulation plant, pollen tube growth testing, and glue-line treatment of engineered wood products. Additionally, product brand names like TAG G2[™], Vixen[™], Taratek[™] and Permatek[™] are widely known in New Zealand.

About Lonza

Lonza is one of the world's leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. We harness science and technology to create products that support safer and healthier living and that enhance the overall quality of life.

Press Release

Not only are we a custom manufacturer and developer, Lonza also offers services and products ranging from active pharmaceutical ingredients and stem-cell therapies to drinking water sanitizers, from the vitamin B compounds and organic personal care ingredients to agricultural products, and from industrial preservatives to microbial control solutions that combat dangerous viruses, bacteria and other pathogens.

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 40 major manufacturing and R&D facilities and approximately 9,800 full-time employees worldwide. The company generated sales of about CHF 3.64 billion in 2014 and is organized into two market-focused segments: Pharma&Biotech and Specialty Ingredients. Further information can be found at www.lonza.com.

Lonza Contact Information

Lonza Group Ltd	Lonza Group Ltd	Lonza Group Ltd
Head Investor Relations	Head Corporate Communications	Head External Communications
Dirk Oehlers	Dominik Werner	Constance Ward
Tel +41 61 316 8540	Tel +41 61 316 8798	Tel +41 61 316 8840
Fax +41 61 316 9540	Fax +41 61 316 9540	Fax +41 61 316 9840
dirk.oehlers@lonza.com	dominik.werner@lonza.com	constance.ward@lonza.com

Additional Information and Disclaimer

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this presentation due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this presentation.